摘要
目的研究巨噬细胞在肝癌组织中的分布,探讨其与临床病理因素及预后的关系。方法采用免疫组化二步法染色和细胞计数分析297例手术切除原发性肝癌患者石蜡标本切片中CD+68巨噬细胞的分布,分析CD+68巨噬细胞数目与临床病理因素关系,探讨其对预后的影响。结果 CD+68巨噬细胞低分布组术后1、2、3年无瘤生存率分别为66.0%、51.9%和45.9%,而高分布组1、2、3年无瘤生存率分别为58.6%、35.8%和29.0%。低分布组患者2年和3年无瘤生存率均好于高分布组,差异有统计学意义(2年对比P=0.0054,3年对比P=0.0026)。CD+68巨噬细胞低分布组1、2、3年总生存率分别为80.0%、65.2%和53.3%,而高分布组1、2、3年总生存率分别为74.7%、46.9%和37.0%。低分布组患者2年和3年总生存率好于高分布组,差异有统计学意义(2年对比P=0.0016,3年对比P=0.0049)。结论肝细胞癌组织中CD+68巨噬细胞与无瘤生存率和总生存率呈负相关,CD+68巨噬细胞越少,预后越好。
Objective To study the expression of CD+ 68 macrophage in hepatocellular carcinoma and to analyze the correlation with the clinicopathological parameters and prognosis of hepatocellular carcinoma. Methods Immunohistochemistry was used to detect the expression of CD+ 68 macrophage in 297 surgical specimens of primary liver cancer. Correlation of CD+ 68 macrophage expression with the clinicopathological parameters and the prognosis of hepatocellular carcinoma was analyzed. Results The disease-free survival rates after hepatectomy at 1,2,and 3 years were 66. 0%,51. 9% and 45. 9% in the low-expression group, respectively,and 58. 6%,35. 8% and 29. 0% in the high-expression group,respectively. The overall survival rates after hepatectomy at 1-,2-,and 3-year were 80. 0%,65. 2% and 53. 3% in the low-expression group,respectively,and 74. 7 %,46. 9% and 37. 0% in the high-expression group,respectively. The postoperative long-term survival of the low-expression group was significantly better than that of the high-expression group. Conclusions The intratumoral CD+ 68 macrophage density has a negative correlation with disease-free survival( DFS) and overall survival( OS) of hepatocellular carcinoma patients.
出处
《中国肿瘤临床与康复》
2013年第12期1322-1324,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
巨噬细胞
肝肿瘤
预后
Macrophage
Hepatocellular neoplasms
Prognosis